CLINICAL TRIALS PROFILE FOR ATENOLOL

All Clinical Trials for Atenolol

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000478 ↗	Asymptomatic Cardiac Ischemia Pilot (ACIP) Study	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1990-11-01	To assess the feasibility of and test the methodology for a full-scale clinical trial of therapies for asymptomatic cardiac ischemia.
NCT00000513 ↗	Trial of Antihypertensive Intervention Management	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1984-04-01	The objective of the Trial of Antihypertensive Intervention Management (TAIM) was to determine the efficacy of dietary management and/or drug therapy, namely thiazide-like diuretics or a beta-blocker, in the control of mild hypertension. Additionally, the Continuation of the Trial of Antihypertensive Intervention Management (COTAIM) tested the effects of long-term weight reduction, and sodium/potassium changes added to weight reduction, as well as the original drug treatment, on the failure rate of blood pressure control.
NCT00000514 ↗	Systolic Hypertension in the Elderly Program (SHEP)	Completed	National Institute on Aging (NIA)	Phase 3	1984-06-01	The primary objective was to assess whether long-term administration of antihypertensive therapy to elderly subjects with isolated systolic hypertension reduced the combined incidence of fatal and non-fatal stroke. The secondary objectives were to evaluate: the effect of long-term antihypertensive therapy on mortality from any cause in elderly people with isolated systolic hypertension; possible adverse effects of chronic use of antihypertensive drug treatment in this population; the effect of therapy on indices of quality-of-life; the natural history of isolated systolic hypertension in the placebo population.
NCT00000514 ↗	Systolic Hypertension in the Elderly Program (SHEP)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1984-06-01	The primary objective was to assess whether long-term administration of antihypertensive therapy to elderly subjects with isolated systolic hypertension reduced the combined incidence of fatal and non-fatal stroke. The secondary objectives were to evaluate: the effect of long-term antihypertensive therapy on mortality from any cause in elderly people with isolated systolic hypertension; possible adverse effects of chronic use of antihypertensive drug treatment in this population; the effect of therapy on indices of quality-of-life; the natural history of isolated systolic hypertension in the placebo population.
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	US Department of Veterans Affairs		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	VA Office of Research and Development		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.

Clinical Trial Conditions for Atenolol

Condition Name

Condition Name for Atenolol
Intervention	Trials
Hypertension	40
Essential Hypertension	6
Marfan Syndrome	6
Healthy	5

Condition MeSH

Condition MeSH for Atenolol
Intervention	Trials
Hypertension	44
Essential Hypertension	9
Cardiovascular Diseases	8
Heart Diseases	7

Clinical Trial Locations for Atenolol

Trials by Country

Trials by Country for Atenolol
Location	Trials
United States	104
Canada	18
Korea, Republic of	7
China	7
Germany	7

Trials by US State

Trials by US State for Atenolol
Location	Trials
Florida	8
Minnesota	8
Massachusetts	7
California	6
New York	6

Clinical Trial Progress for Atenolol

Clinical Trial Phase

Clinical Trial Phase for Atenolol
Clinical Trial Phase	Trials
Phase 4	48
Phase 3	27
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Atenolol
Clinical Trial Phase	Trials
Completed	78
Unknown status	19
Terminated	6

Clinical Trial Sponsors for Atenolol

Sponsor Name

Sponsor Name for Atenolol
Sponsor	Trials
National Heart, Lung, and Blood Institute (NHLBI)	7
University of Florida	4
Assaf-Harofeh Medical Center	4

Sponsor Type

Sponsor Type for Atenolol
Sponsor	Trials
Other	123
Industry	50
NIH	11

Atenolol: Clinical Trials, Market Analysis, and Projections

Clinical Trials and Safety Evaluation

Atenolol, a beta-1 selective blocker, is undergoing various clinical trials to assess its efficacy and safety in different medical conditions.

Phases of Clinical Trials

Clinical trials for atenolol, like other drugs, go through several phases. Here’s a brief overview:

• Phase 0: These are small trials that help decide if a new agent should be tested in a phase 1 trial. They are not commonly used for established drugs like atenolol[1].
• Phase 1 and 2: These phases focus on safety, side effects, optimal dosages, and the risks/benefits of the drug. For example, a study is evaluating whether atenolol is effective and safe for preventing bone loss in postmenopausal women[1].
• Phase 3: This phase involves large numbers of participants to compare the new treatment with the current standard therapy, ensuring the results are valid and assessing long-term safety and efficacy[1].
• Phase 4: Conducted after the drug has been approved, these trials look at long-term safety and effectiveness in a broader population[1].

Specific Trials

One notable trial is the "Atenolol for the Prevention of Osteoporosis (APO)" study, which aims to evaluate the safety and efficacy of atenolol in preventing bone loss in postmenopausal women[1].

Another study involves the use of atenolol in the outpatient management of alcohol withdrawal syndrome. This randomized, double-blind clinical trial found that atenolol improved treatment outcomes by reducing withdrawal symptoms and craving levels compared to a placebo[4].

Market Analysis

The atenolol market is experiencing significant growth driven by several key factors.

Market Size and Growth

As of 2025, the global atenolol market is valued at approximately USD 13.33 billion, up from USD 12.23 billion in 2024. It is projected to grow to USD 24.53 billion by 2037, with a compound annual growth rate (CAGR) of over 5.5% during the forecast period[2][3].

Growth Drivers

Several factors are driving this growth:

• Increasing Prevalence of Hypertension: The global prevalence of hypertension is rising, with an estimated 1.28 billion people aged 30-79 years affected worldwide. This is particularly high in low- and middle-income countries[2][3].
• Aging Population: The global population of people aged 60 and above is expected to increase from 1 billion in 2020 to 1.4 billion by 2030 and 2.1 billion by 2050, leading to higher demand for antihypertensive drugs[2][3].
• Poor Lifestyle and Dietary Habits: Increasingly poor lifestyle choices and dietary habits are contributing to the rise in cardiovascular diseases, further boosting the demand for atenolol[2][3].

Market Segmentation

The atenolol market is segmented by application and distribution channel:

• Application: The hypertension segment is expected to dominate, accounting for about 55% of the market share by 2037 due to the increasing prevalence of hypertension worldwide[2].
• Distribution Channel: Hospital pharmacies are expected to hold a significant share, around 49% by 2037, due to the rising patient pool and increasing number of hospitals. Online pharmacies are also expected to grow significantly due to rising awareness and internet penetration[2].

Regional Market

The Asia Pacific region is anticipated to be the second largest market, driven by the rising burden of hypertension and changing lifestyles. Europe is also expected to hold a noteworthy share, driven by the high incidence of cardiovascular diseases and efficient healthcare facilities[2][3].

Projections and Trends

Future Growth

The atenolol market is expected to continue its strong growth trajectory, reaching $15.85 billion by 2028 with a CAGR of 7.2% during the forecast period. Key trends include:

• Demand for Beta-1 Selective Blockers: The increasing demand for beta blockers, particularly beta-1 selective blockers like atenolol, is a significant trend[3][5].
• New Formulations: Recent regulatory approvals for new formulations, including extended-release formulations, are expected to drive market growth[3][5].
• Combination Therapies: There is a rising demand for combination therapies in treating cardiovascular conditions, which will further boost the atenolol market[3][5].

Impact of Regulatory Approvals

Regulatory approvals, such as the ANDA authorization from the USFDA for Unichem Laboratories Limited's Atenolol and Chlorthalidone Tablets, will support market growth by increasing the availability of generic versions of atenolol-based treatments[2].

"The atenolol market size is expected to see strong growth in the next few years. It will grow to $15.85 billion in 2028 at a compound annual growth rate (CAGR) of 7.2%." - GlobeNewswire[3]

Key Takeaways

• Clinical Trials: Atenolol is being evaluated in various clinical trials for its safety and efficacy in different conditions, including osteoporosis prevention and alcohol withdrawal management.
• Market Growth: The global atenolol market is projected to grow significantly, driven by the increasing prevalence of hypertension, an aging population, and poor lifestyle choices.
• Market Segmentation: The market is segmented by application, with hypertension being the dominant segment, and by distribution channel, with hospital pharmacies holding a significant share.
• Regional Trends: The Asia Pacific and European regions are expected to be key markets due to their high incidence of cardiovascular diseases and efficient healthcare facilities.
• Future Trends: The market will be driven by the demand for beta-1 selective blockers, new formulations, and combination therapies.

FAQs

What is the current market size of atenolol?

The current market size of atenolol is approximately USD 13.33 billion as of 2025[2].

What are the primary drivers of the atenolol market growth?

The primary drivers include the increasing prevalence of hypertension, a significant rise in the aging population, and poor lifestyle and dietary habits leading to cardiovascular issues[2][3].

Which segment is expected to dominate the atenolol market by application?

The hypertension segment is expected to dominate, accounting for about 55% of the market share by 2037[2].

What are the key trends anticipated in the atenolol market?

Key trends include the demand for beta-1 selective blockers, recent regulatory approvals for new formulations, the development of extended-release formulations, and a rising demand for combination therapies in treating cardiovascular conditions[3][5].

Which regions are expected to be significant in the atenolol market?

The Asia Pacific and European regions are expected to be significant due to their high incidence of cardiovascular diseases and efficient healthcare facilities[2][3].

Sources

1. Mayo Clinic - Atenolol for the Prevention of Osteoporosis (APO)[1]
2. Research Nester - Atenolol Market Size & Share, Growth Forecasts 2025-2037[2]
3. GlobeNewswire - Atenolol Market Report 2024: Growing Demand for Beta-1 Selective Blockers[3]
4. JAMA Network - The Efficacy of Atenolol in the Outpatient Management of the Alcohol Withdrawal Syndrome[4]
5. ResearchAndMarkets - Atenolol Global Market Size, Competitors, Trends & Forecast[5]

Last updated: 2025-01-07